XRAY on Nasdaq

Dentsply Sirona

Logo: Grmike, Public domain, via Wikimedia Commons6

Healthcare Company

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.3 Its shares trade on Nasdaq under the symbol XRAY.1 Wikipedia text CC BY-SA 4.0

$8.76 up 0.32 (3.82%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 20, 2026.

Overview

1899Founded1

Compare with Envista Holdings Corporation, SmileDirectClub or Sonendo (United States), or pick any stock.

  • TickerXRAY on Nasdaq1
  • Industrydentistry1
  • HeadquartersYork1
  • Websitewww.dentsplysirona.com/en
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address13320 Ballantyne Corporate Place, Charlotte, Nc 28277-36077
  • Filer categoryLarge accelerated filer7
  • LEI9NHEHR1SOZCYXDO8HO284
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O UNITED AGENT GROUP INC., 19803 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 20029514

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

50.0%Gross margin10
-11.5%Operating margin10
-16.2%Net margin10
-3.0%Revenue growth, 202510
-44.7%Return on equity10
1.50×Debt to equity10

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Essential Dental Solutions brought in 40% of the revenue Dentsply Sirona broke down this way in fiscal 2025.

  1. Essential Dental Solutions$1.5B1040%up 1% from 2024
  2. Connected Technology Solutions$1.0B1028%down 2% from 2024
  3. Orthodontic And Implant Solutions$850.0M1023%down 13% from 2024
  4. Wellspect Healthcare$325.0M109%up 7% from 2024
Business segments by year
Business segments202320242025
Essential Dental Solutions$1.5B$1.5B$1.5B
Connected Technology Solutions$1.2B$1.1B$1.0B
Orthodontic And Implant Solutions$1.0B$973.0M$850.0M
Wellspect Healthcare$288.0M$304.0M$325.0M

Regions

Other Foreign brought in 34% of the revenue Dentsply Sirona broke down this way in fiscal 2025.

  1. Other Foreign$2.1B1034%up 2% from 2024
  2. Europe$1.6B1026%up 4% from 2024
  3. United States$1.2B1019%down 12% from 2024
  4. Rest of the World$922.0M1015%down 1% from 2024
  5. Germany$422.0M107%up 3% from 2024
Regions by year
Regions202320242025
Other Foreign$2.1B$2.0B$2.1B
Europe$1.6B$1.5B$1.6B
United States$1.4B$1.3B$1.2B
Rest of the World$978.0M$927.0M$922.0M
Germany$431.0M$410.0M$422.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue50¢$1.8B
  • Research and development4¢$150.0M
  • Selling, general and admin39¢$1.4B
  • Other costs4¢$140.0M
  • Income tax3¢$112.0M

Out of $3.7B in revenue.10 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Dividends paid54¢$128.0M
  • Kept or used elsewhere46¢$107.0M

Out of $235.0M of cash from operations.10

Financial statements

Revenue1112131410$3.7B in 2025−9% since 2019
0$2.0B$4.0B$6.0B2019: $4.0B$4.0B20192020: $3.3B$3.3B2020−17%2021: $4.2B$4.2B2021+27%2022: $3.9B$3.9B2022−7%2023: $4.0B$4.0B2023+1%2024: $3.8B$3.8B2024−4%2025: $3.7B$3.7B2025−3%
Gross profit1112131410$1.8B in 2025−15% since 2019
0$1.0B$2.0B$3.0B2019: $2.2B$2.2B20192020: $1.7B$1.7B2020−23%2021: $2.3B$2.3B2021+42%2022: $2.1B$2.1B2022−9%2023: $2.1B$2.1B2023−2%2024: $2.0B$2.0B2024−6%2025: $1.8B$1.8B2025−6%
Operating income1112131410-$422.0M in 2025
-$1.0B-$500.0M0$500.0M$1.0B2019: $353.0M$353.0M20192020: -$3.0M-$3.0M20202021: $608.0M$608.0M20212022: -$937.0M-$937.0M20222023: -$85.0M-$85.0M2023−91%2024: -$879.0M-$879.0M2024+934%2025: -$422.0M-$422.0M2025−52%
Net income1112131410-$598.0M in 2025
-$1.0B-$500.0M0$500.0M2019: $256.0M$256.0M20192020: -$73.0M-$73.0M20202021: $411.0M$411.0M20212022: -$950.0M-$950.0M20222023: -$132.0M-$132.0M2023−86%2024: -$910.0M-$910.0M2024+589%2025: -$598.0M-$598.0M2025−34%

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Net sales$3.7B$3.8B$4.0B
Cost of products sold$1.8B$1.8B$1.9B
Gross profit$1.8B$2.0B$2.1B
Selling, general, and administrative expenses$1.4B$1.6B$1.6B
Research and development expenses$150.0M$165.0M$184.0M
Goodwill and intangible asset impairments$650.0M$1.0B$307.0M
Restructuring costs$24.0M$53.0M$67.0M
Operating loss-$422.0M-$879.0M-$85.0M
Interest expense, net$88.0M$69.0M$81.0M
Other (income) expense, net-$24.0M-$12.0M$9.0M
Loss before income taxes-$486.0M-$936.0M-$175.0M
Provision (benefit) for income taxes$112.0M-$26.0M-$43.0M
Net loss-$598.0M-$910.0M-$132.0M
Less: Net loss attributable to noncontrolling interests$0$0$0
Net loss attributable to Dentsply Sirona-$598.0M-$910.0M-$132.0M
Basic (in dollars per share)-$3.00-$4.48-$0.62
Diluted (in dollars per share)-$3.00-$4.48-$0.62
Basic (in shares)199.4M shares203.2M shares212.0M shares
Diluted (in shares)199.4M shares203.2M shares212.0M shares

Compare Dentsply Sirona with another company

Corporate structure

Dentsply Sirona sits at the top of its group. 135 entities, 45 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Dentsply Sirona

  • Southpoint Capital Advisors LP Filed SCHEDULE 13G/A on Dentsply Sirona, latest Aug 14, 2026 (2 filings since Mar 18, 2026)
  • AQR CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Dentsply Sirona, latest Aug 13, 2026 (3 filings since Aug 14, 2025)
  • First Eagle Investment Management, LLC Filed SCHEDULE 13G/A on Dentsply Sirona, latest Aug 6, 2026 (2 filings since Nov 12, 2024)
  • BlackRock Filed SCHEDULE 13G/A on Dentsply Sirona, latest Jul 8, 2026 (3 filings since Oct 21, 2024)
  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Dentsply Sirona, latest Apr 29, 2026
  • VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Dentsply Sirona, latest Apr 29, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Dentsply Sirona, latest Mar 26, 2026 (7 filings since Feb 9, 2022)
  • LAZARD ASSET MANAGEMENT LLC Filed SCHEDULE 13G on Dentsply Sirona, latest Feb 17, 2026 (2 filings since Aug 14, 2025)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G/A on Dentsply Sirona, latest Nov 14, 2025 (3 filings since Nov 14, 2024)
  • NUANCE INVESTMENTS, LLC Filed SCHEDULE 13G/A on Dentsply Sirona, latest May 12, 2025 (4 filings since Feb 8, 2023)
  • Artisan Partners Limited Partnership Filed SC 13G/A on Dentsply Sirona, latest Nov 12, 2024 (4 filings since Feb 4, 2022)
  • FULLER & THALER ASSET MANAGEMENT, INC. Filed SC 13G on Dentsply Sirona, latest Nov 12, 2024
  • Dentsply Sirona Charlotte, North Carolina, United States
    • Dentsply Sirona (Sweden) Subsidiary
    • DENTSPLY INDIA PRIVATE LIMITED Subsidiary · 99.99% · New Delhi, India
    • 1. ARGE ÖGK Subsidiary · Austria
    • 10. Dentsply (Tianjin) International Trading Co. Ltd. Subsidiary · China
    • 100. SIRONA Immobilien GmbH Subsidiary · Germany
    • 101. Sirona Technologie GmbH & Co. KG Subsidiary · Germany
    • 102. SIRONA Verwaltungs GmbH Subsidiary · Germany
    • 103. Societe de Recherche Techniques Dentaires SAS Subsidiary · France
    • 104. Straight Smile, LLC Subsidiary · Delaware, United States
    • 105. The Dental Trading Co., Ltd. Subsidiary · Thailand
    • 106. Tulsa Dental Products LLC Subsidiary · Delaware, United States
    • 107. VDW GmbH Subsidiary · Germany
    • 108. VIPI Indústria, Comércio, Exportação e Importação de Produtos Odontológicos Ltda. Subsidiary · Brazil
    • 109. Wellspect AB Subsidiary · Sweden
    • 11. Dentsply Argentina S.A.C.e.I. Subsidiary · Argentina
    • 110. Wellspect AG Subsidiary · Switzerland
    • 111. Wellspect ApS Subsidiary · Denmark
    • 112. Wellspect AS Subsidiary · Norway
    • 113. Wellspect B.V. Subsidiary · Netherlands
    • 114. Wellspect DTC LLC Subsidiary · Delaware, United States
    • 115. Wellspect GmbH Subsidiary · Germany
    • 116. Wellspect Healthcare GmbH Subsidiary · Austria
    • 117. Wellspect Inc. Subsidiary · Delaware, United States
    • 118. Wellspect Ltd. Subsidiary · United Kingdom
    • 119. Wellspect Medikal Urunler Kimya Turizm Sanayi Ve Ticaret Anonim Sirketi Subsidiary · Turkey
    • and 109 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Dentsply Sirona reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Finance-lease assets$010 Dec 31, 2025$010 Dec 31, 2024
Operating-lease assets (leased space)$139.0M10 Dec 31, 2025$136.0M10 Dec 31, 2024+2.2%

Real estate and locations

ItemLatestA year beforeChange
Countries it operates in14010 Dec 31, 202515014 Dec 31, 2024−6.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$326.0M10 Dec 31, 2025$272.0M10 Dec 31, 2024+19.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.1B10 Dec 31, 2025$1.6B10 Dec 31, 2024−28.1%
Intangible assets, net (excluding goodwill)$974.0M10 Dec 31, 2025$1.2B10 Dec 31, 2024−19.3%
Indefinite-lived intangibles (excluding goodwill)$256.0M10 Dec 31, 2025$337.0M10 Dec 31, 2024−24.0%
Finite-lived intangibles, gross$3.0B10 Dec 31, 2025$2.8B10 Dec 31, 2024+8.7%
Accumulated amortization$2.3B10 Dec 31, 2025$1.9B10 Dec 31, 2024+20.7%
Finite-lived intangibles, net$718.0M10 Dec 31, 2025$870.0M10 Dec 31, 2024−17.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$642.0M10 Dec 31, 2025$564.0M10 Dec 31, 2024+13.8%
Raw materials$199.0M10 Dec 31, 2025$172.0M10 Dec 31, 2024+15.7%
Work in process$82.0M10 Dec 31, 2025$72.0M10 Dec 31, 2024+13.9%
Finished goods$361.0M10 Dec 31, 2025$320.0M10 Dec 31, 2024+12.8%

Properties, in its own words

The following is a listing of Dentsply Sirona’s principal manufacturing and distribution locations:

Location · Function · Leasedor Owned

The rest of Item 2

United States:

Milford, Delaware (2) · Manufacture of dental consumable products · Owned

Sarasota, Florida (2) (3) · Manufacture of orthodontic accessory products and dental consumable products · Owned

Waltham, Massachusetts (3) · Manufacture and distribution of dental implant products · Leased

Lancaster, Pennsylvania (5) · Distribution of dental consumable and dental equipment products · Leased

York, Pennsylvania (1) (2) · Manufacture and distribution of dental equipment products · Owned

Johnson City, Tennessee (2) · Manufacture and distribution of endodontic instruments and materials · Leased

Foreign:

Pirassununga, Brazil (3) · Manufacture and distribution of artificial teeth and dental consumable products · Owned

Bensheim, Germany (1) · Manufacture and distribution of dental equipment · Owned

Hanau, Germany (3) · Manufacture and distribution of precious metal dental alloys, dental ceramics and dental implant products · Owned

Konstanz, Germany (2) · Manufacture and distribution of dental consumable products · Owned

Munich, Germany (2) · Manufacture and distribution of endodontic instruments and materials · Owned

Bar Lev Industrial Park, Israel (3) · Manufacture and distribution of dental implant products · Owned/Leased

Badia Polesine, Italy (2) · Manufacture and distribution of dental consumable products · Owned/Leased

Venlo, Netherlands (5) · Distribution of dental consumable products · Leased

Mölndal, Sweden (3) (4) · Manufacture and distribution of dental implant products and healthcare consumable products · Owned

Ballaigues, Switzerland (2) · Manufacture and distribution of endodontic instruments, plastic components and packaging material · Owned

Ankara, Turkey (4) · Manufacture and distribution of healthcare consumable products · Owned

Mexicali, Mexico (3) · Manufacture of orthodontic products · Leased

San Jose Province, Costa Rica (3) · Service provider of orthodontic products · Leased

(1) These properties are included in the Connected Technology Solutions segment.

(2) These properties are included in the Essential Dental Solutions segment.

(3) These properties are included in the Orthodontic and Implant Solutions segment.

(4) These properties are included in the Wellspect Healthcare segment.

(5) These properties are distribution warehouses not managed by named segments.

In addition, the Company maintains sales and distribution offices at certain of our foreign and domestic manufacturing facilities, as well as at various other U.S. and international locations. Most of these sites around the world that are used exclusively for sales and distribution are leased. We conduct research and development across various locations around the world, including at our leased Innovation Center located in Charlotte, North Carolina. We also lease our worldwide headquarters located in Charlotte, North Carolina and our shared service center in Bratislava, Slovakia. We believe that our properties and facilities are well maintained and are generally suitable and adequate for the purposes for which they are used.

Item 2 of the 10-K filed Feb 26, 2026.18

The story

Name

The name Dentsply Sirona International is a compound of the names of two distinct dental technology companies: Dentsply and Sirona Dental Systems, respectively. The current name is the result of a merger between the two companies in 2016.

Sirona Dental Systems

Sirona Dental Systems was founded in 1877 in Erlangen, Germany.

1899–2000

Dentsply Incorporated was founded as Dentist's Supply Company in New York City in 1889 when a proposed business charter filed by three men - Dr. Jacob Frick Franz, John Sheppard, and Dean Osborne - was approved by the acting Commissioner of Deeds of New York City, Lewis Fawcett. Starting with an investment of $10,000 (roughly equivalent to $377,080 in 2024), the charter stipulated that the corporation would last fifty years pending renewal. Shortly after its founding, the company made its first acquisition, a Pennsylvania porcelain teeth manufacturer. One of the four founders, George H. Whiteley became the main operator of the company as a result of his experience as a ceramicist. Whiteley's contributions to the company were invaluable as he was responsible for many innovations such as a patented process involving platinum rings that reduced tooth breakage. Other innovations (credited to doctors like James Williams who were hired by the company for research purposes) included better fitting dentures, tooth size for people of different face shapes and age specific colored teeth.

In the early 1920s, the company selected European distributor E. de Trey & Sons as its primary marketer to Europe, however it quickly became the company's main distributor in the US also. A rivalry between De Trey and the main other denture equipment producer at the time, Ash Company, nearly eliminated cash flows due to extreme price cutting. The problem was resolved when the two decided to merge their distribution businesses into one named the Amalgamated Dental Company Limited. In 1925, 45% of Zahnfabrik (artificial teeth producer) was bought by Dentists' Supply and its distributor Amalgamated Dental bought a 30% interest in the manufacturer.

High American tariffs and increased efforts to gain market share abroad, especially in Europe and Australia, led the company to set up more research and manufacturing centers abroad. Its first foreign subsidiary was established in Australia as a means to acquire Natudryl Manufacturing. In the 1950s and 1960s, the company developed many of the ideas used by its equipment today like tooth cleaning machine Dentsply Cavitron and Neolux which improved the finish of plastic teeth. The company renamed itself Dentsply International in 1969 due to its products' brand name being more widely recognized.

Key acquisitions by Dentists' Supply Company: LD Caulk Company in 1963, Ransom and Randolph Company in 1964, F&F Koenigkramer Company (chairs and stools). Largest was Amalgamated Dental Industrial (former distributor that played a major role in helping the company grow early on that also controlled Australia's largest dental supply chain) in 1976.

In 1993, after it acquired Gendex Corporation in a reverse takeover, the company went public on the NASDAQ. The new company then purchased medical X-ray tubes supplier Eureka X-Ray Inc., which was key since Gendex was a major manufacturer of X-ray systems (Eureka X-Ray was later sold in 1994). Healthco, its main distributor in the US, went bankrupt in 1993.

2000–present

In 2010, the most important markets for sales were Europe & CIS (40%), USA (37%), Latin America (5%), Asia (excl CIS and Japan, 5%), Canada (4%), Japan (4%), Middle East & Africa (3%) and Australia (2%). Dentsply holds a leading market share in the dental restorative sector ($4.0 billion according to the company).

Read the full text

In June 2011, Dentsply acquired Astra Tech, the world's third largest maker of dental implants from the Anglo-Swedish pharmaceutical company AstraZeneca for $1.8 billion. The deal raises revenue by 25% ($535M) and was completed on August 31, 2011. Acquisitions in 2011 caused the value of long term debt to increase by 147% while total assets grew by 146% (current assets however decreased in value). Acquisition/restructuring charges were one of the reasons net income decreased 7.4%.

Markets outside the United States are becoming increasingly important: they accounted for 67% of Dentsply revenue in 2013 steady with 2012 but up from 66% and 63% the previous two years.

In 2012, acquisitions contributed all of the growth in sales (16.2%, currency effects were -3.8%). 2012 sales growth by region: Europe 27.5% (vs 17.9% in 2011), USA 13.8% (vs 4.9%), elsewhere 15.9% (vs 9.4%). 88% of net sales were in dental products, 12% from consumable medical device products (casting industry).

On February 29, 2016 Dentsply combined with Long Island-based Sirona Dental Systems in a $14.5 billion merger of equals. While both supply dental products, Sirona's business centers on dental equipment in contrast with Dentsply's consumables.

In October 2017, CEO Jeffrey Slovin, executive chairman Bret Wise, and president Christopher Clark all resigned. On January 17, 2018, Dentsply Sirona announced the appointment of Donald Casey Jr., formerly CEO of the Medical Segment of Cardinal Health, as CEO and a member of the board, with Casey to take the role in February and succeed interim CEO Mark Thierer.

In January 2021, Dentsply announced the acquisition of Byte, a company specializing in orthodontics, for $1.04 billion.

In April 2022, Dentsply Sirona fired CEO Donald Casey. The interim CEO was announced to be John Groetelaars. In September 2022, Simon Campion was announced as the full-time CEO replacing Don Casey. Both former CEO Donald Casey and former CFO Jorge Gomez are under investigation by Dentsply Sirona Inc. and the SEC for securities fraud.

In June 2023, it was reported by the Chief Executive Leadership institute of the Yale School of Management that the company continued to do "business as usual" in Russia while many others had wound down or curtailed their operations there in the wake of the full-scale invasion of Ukraine.This decision has been widely criticized as enabling the Russian economy and, by extension, its war effort, undermining global solidarity against the aggression and raising ethical concerns about the company's commitment to social responsibility.

On July 21st, 2025, Dentsply Sirona announced Daniel Scavilla will become President and Chief Executive Officer starting on August 1st, 2025. Daniel will replace current CEO Simon Campion.

From Wikipedia’s article on Dentsply Sirona, shared under CC BY-SA 4.0.8

Leadership

Who has led Dentsply Sirona, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (76)

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • 1. ARGE ÖGK Austria, 85%9
  • 10. Dentsply (Tianjin) International Trading Co. Ltd. China9
  • 100. SIRONA Immobilien GmbH Germany9
  • 101. Sirona Technologie GmbH & Co. KG Germany9
  • 102. SIRONA Verwaltungs GmbH Germany9
  • 103. Societe de Recherche Techniques Dentaires SAS France9
  • 104. Straight Smile, LLC Delaware9
  • 105. The Dental Trading Co., Ltd. Thailand9
  • 106. Tulsa Dental Products LLC Delaware9
  • 107. VDW GmbH Germany9
  • 108. VIPI Indústria, Comércio, Exportação e Importação de Produtos Odontológicos Ltda. Brazil9
  • 109. Wellspect AB Sweden9
  • 11. Dentsply Argentina S.A.C.e.I. Argentina9
  • 110. Wellspect AG Switzerland9
  • 111. Wellspect ApS Denmark9
  • 112. Wellspect AS Norway9
  • 113. Wellspect B.V. Netherlands9
  • 114. Wellspect DTC LLC Delaware9
  • 115. Wellspect GmbH Germany9
  • 116. Wellspect Healthcare GmbH Austria9
  • 117. Wellspect Inc. Delaware9
  • 118. Wellspect Ltd. United Kingdom9
  • 119. Wellspect Medikal Urunler Kimya Turizm Sanayi Ve Ticaret Anonim Sirketi Turkey9
  • 12. Dentsply BX Sarl Luxembourg9
All 126 listed subsidiaries
  • 120. Wellspect Oy Finland9
  • 121. Wellspect S.A.S. France9
  • 122. Wellspect S.L. Spain9
  • 123. Wellspect Srl Italy9
  • 124. Zetta Digital Healthcare Technology (Suzhou) Ltd. China9
  • 125. Zetta25 AG Switzerland9
  • 126. Zhermack GmbH Deutschland Germany9
  • 127. Zhermack SpA Italy9
  • 128. ZST Holdings Inc. Canada, 16.2%9
  • 13. Dentsply Canada Ltd. Canada9
  • 14. Dentsply CH Sarl Luxembourg9
  • 15. Dentsply Chile Comercial Limitada Chile9
  • 16. Dentsply De Trey GmbH Germany9
  • 17. Dentsply Dental (Tianjin) Co. Ltd. China9
  • 18. Dentsply Dental B.V. Netherlands9
  • 19. Dentsply Dental S.a.r.l. Luxembourg9
  • 2. Augma Bio Materials Ltd. Israel, 20%9
  • 20. Dentsply Europe S.a.r.l. Luxembourg9
  • 21. DENTSPLY Finance Co. LLC Delaware9
  • 22. Dentsply GAC Europe SAS France9
  • 23. Dentsply IH A/S Denmark9
  • 24. Dentsply IH AB Sweden9
  • 25. Dentsply IH AS Norway9
  • 26. Dentsply IH GmbH Germany9
  • 27. Dentsply IH Holdings GmbH Germany9
  • 28. Dentsply IH Inc. Delaware9
  • 29. Dentsply IH Ltd United Kingdom9
  • 3. Byte AU Pty. Ltd. Australia9
  • 30. Dentsply IH Oy Finland9
  • 31. Dentsply Implants Manufacturing GmbH Germany9
  • 32. Dentsply Implants NV Belgium9
  • 33. Dentsply India Pvt. Ltd. India9
  • 34. Dentsply Industria e Comercio Ltda. Brazil9
  • 35. Dentsply Israel Ltd. Israel9
  • 36. Dentsply Limited Cayman Islands9
  • 37. Dentsply LLC Delaware9
  • 38. Dentsply Mexico, S.A. de C.V. Mexico9
  • 39. DENTSPLY North America LLC Delaware9
  • 4. Byte AU Unit Trust Australia9
  • 40. Dentsply Portugal, Unipessoal. Lda. Portugal9
  • 41. Dentsply Russia Limited United Kingdom9
  • 42. Dentsply Sirona (N.Z.) Limited New Zealand9
  • 43. DENTSPLY SIRONA (PHILS.), INC. Philippines, 99.999%9
  • 44. Dentsply Sirona (Thailand) Co., Ltd. Thailand9
  • 45. Dentsply Sirona Arabia Regional Headquarter Saudi Arabia9
  • 46. Dentsply Sirona Austria GmbH Austria9
  • 47. Dentsply Sirona Benelux B.V. Netherlands9
  • 48. Dentsply Sirona Benelux NV Belgium9
  • 49. Dentsply Sirona Dental Solutions (Shanghai) Co. Ltd. China9
  • 5. Clear Blue Smiles, Inc. Delaware, 15%9
  • 50. Dentsply Sirona Deutschland GmbH Germany9
  • 51. Dentsply Sirona Europe GmbH Austria9
  • 52. Dentsply Sirona France S.A.S. France9
  • 53. Dentsply Sirona Holdings Inc. Delaware9
  • 54. Dentsply Sirona Iberia S.A. Spain9
  • 55. Dentsply Sirona Italia SrL Italy9
  • 56. DENTSPLY Sirona K.K. Japan9
  • 58. Dentsply Sirona Limited Liability Company Russia9
  • 59. Dentsply Sirona Malaysia Sdn Bhd Malaysia9
  • 6. Datum Biotech Ltd. Israel9
  • 60. Dentsply Sirona Orthodontics Inc. Delaware9
  • 61. Dentsply Sirona Pty. Ltd. Australia9
  • 62. Dentsply Sirona Real Estate GmbH Germany9
  • 63. Dentsply Sirona Reinsurance Limited Bermuda9
  • 64. Dentsply Sirona Repair Center (US) LLC Delaware9
  • 65. Dentsply Sirona Repair Centre (UK) Limited United Kingdom9
  • 66. Dentsply Sirona Schweiz AG Switzerland9
  • 67. Dentsply Sirona Singapore Pte. Ltd. Singapore9
  • 68. Dentsply Sirona Slovakia s.r.o. Slovakia9
  • 69. Dentsply Sirona South Africa (Proprietary) Limited South Africa9
  • 7. Datum Dental Ltd. Israel9
  • 70. Dentsply Sirona Sweden AB Sweden9
  • 71. Dentsply Sirona US LLC Delaware9
  • 72. Dentsply Sirona Vietnam Company Limited Vietnam9
  • 73. Dentsply Sweden AB Sweden9
  • 74. Dentsply Turkey Diş Hekimliği Ürünleri A.Ş Turkey9
  • 75. Dentsply Ukraine LLC Ukraine9
  • 76. Dentsply US Inc. Delaware9
  • 77. DS Dental Instruments SRL Barbados9
  • 78. DS International Services Inc. Delaware9
  • 79. DS Rep B.V. Netherlands9
  • 8. DeguDent GmbH Germany9
  • 80. E.S. Tooling NV Belgium9
  • 81. JCM International Inc. Delaware9
  • 82. Maillefer Instruments Holding S.a.r.l. Switzerland9
  • 83. Maillefer Instruments Plus Sarl Switzerland9
  • 85. MIS Implants Technologies Ltd. Israel9
  • 86. New Britain Medical Supplies, Inc. Connecticut9
  • 87. Ohio IC Company Delaware9
  • 88. OraMetrix GmbH Germany9
  • 89. OraMetrix S.R.L. Costa Rica9
  • 9. Dentsply - Sirona Poland SP.z.o.o Poland9
  • 90. Ortho Concept Sarl France9
  • 91. Orthodental, S.A. de C.V. Mexico9
  • 92. PT Dentsply Indonesia Indonesia9
  • 93. SCI 2R France9
  • 94. Sirona Dental Comércio de Produtos e Sistemas Odontológicos Ltda. Brazil9
  • 95. Sirona Dental GmbH Austria9
  • 96. SIRONA Dental Systems GmbH Germany9
  • 97. Sirona Dental Systems LLC Russia9
  • 98. Sirona Dental Systems Trading, LLC United Arab Emirates9
  • 99. Sirona Dental, Inc. Delaware9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • DENTSPLY INTERNATIONAL INC /DE/Feb 13, 1995 to Feb 29, 20167

Timeline

  1. Aug 7, 20268-K Results of operations114
  2. Aug 6, 20268-K Financial statements and exhibits115
  3. Jun 11, 20268-K Executive or director change; Regulation FD disclosure116
  4. Jun 4, 20268-K Shareholder vote117
  5. May 5, 20268-K Results of operations118
  6. Feb 26, 20268-K Results of operations119
  7. Feb 24, 20268-K Executive or director change; Regulation FD disclosure120
  8. Jan 14, 20268-K Regulation FD disclosure121
  9. Jan 13, 20268-K Executive or director change; Regulation FD disclosure122
  10. Dec 31, 20258-K Entered a material agreement; New debt or obligation123
  11. Nov 25, 20258-K Other events124
  12. Nov 7, 20258-K Executive or director change125
  13. Aug 12, 2025New chief executive Daniel T. Scavilla becomes CEO19
  14. Nov 16, 2022New chief executive John P. Groetelaars becomes CEO21
  15. Sep 19, 2022New chief executive Simon D. Campion becomes CEO20
  16. Feb 20, 2018New chief executive Donald M. Casey Jr. becomes CEO22
  17. Mar 2, 2016New chief executive James G. Mosch becomes CEO25
  18. Mar 2, 2016New chief executive Christopher T. Clark becomes CEO24
  19. Mar 1, 2016New chief executive Jeffrey Slovin becomes CEO23
  20. Feb 14, 2007New chief executive Bret W. Wise becomes CEO26
  21. Mar 23, 2006New chief executive Gary K. Kunkle Jr. becomes CEO27
  22. Apr 25, 1991Went public Listed on NASDAQ1
  23. 1899Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.37 a share, on Nov 6, 2025.126

When it reported results

  1. Aug 7, 2026Reported quarterly or annual results114
  2. May 5, 2026Reported quarterly or annual results118
  3. Feb 26, 2026Reported quarterly or annual results119
  4. Nov 6, 2025Reported quarterly or annual results127
  5. Aug 7, 2025Reported quarterly or annual results128
  6. Jul 21, 2025Reported quarterly or annual results129
  7. May 8, 2025Reported quarterly or annual results130
  8. Feb 27, 2025Reported quarterly or annual results131

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

743 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 78 major events, 559 insider forms, 40 large holders, 42 other. The latest 20:

  1. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 13, 2026SCHEDULE 13G EDGAR
  4. Aug 12, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 11, 20264 PRIMARY DOCUMENT EDGAR
  6. Aug 7, 20268-K/A EDGAR
  7. Aug 6, 2026SCHEDULE 13G/A EDGAR
  8. Aug 6, 202610-Q EDGAR
  9. Aug 6, 20268-K EDGAR
  10. Jul 21, 20263 PRIMARY DOCUMENT EDGAR
  11. Jul 8, 2026SCHEDULE 13G/A EDGAR
  12. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  13. Jun 26, 2026S-8 EDGAR
  14. Jun 18, 20264/A PRIMARY DOCUMENT EDGAR
  15. Jun 18, 20263 PRIMARY DOCUMENT EDGAR
  16. Jun 16, 20264 PRIMARY DOCUMENT EDGAR
  17. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  18. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  19. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  20. Jun 15, 20264 PRIMARY DOCUMENT EDGAR

The 743 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 25 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 15, 2026HOSEIN CLYDEDirectorBuy6,500$9.99$64.9KForm 4
Jun 15, 2026Gladden Brian TDirectorBuy9,985$10.02$100.0KForm 4
Jun 12, 2026MAZELSKY JONATHAN JAYDirectorBuy10,000$10.14$101.4KForm 4
Jun 12, 2026MCKEON BRIAN PDirectorBuy10,000$10.12$101.2KForm 4
Jun 11, 2026HOLDEN BETSY DDirectorBuy10,086$9.88$99.7KForm 4
Jun 11, 2026Barber Michael JDirectorBuy15,175$9.89$150.1KForm 4
Mar 9, 2026LUCIER GREGORY TDirectorBuy15,000$12.45$186.8KForm 4
Mar 9, 2026Forbes James DDirectorBuy5,000$12.48$62.4KForm 4
Mar 3, 2026LUCIER GREGORY TDirectorBuy22,445$14.03$314.9KForm 4
Mar 3, 2026Forbes James DDirectorBuy5,000$13.47$67.3KForm 4
Mar 2, 2026LUCIER GREGORY TDirectorBuy27,555$14.25$392.7KForm 4
Dec 8, 2025LUCIER GREGORY TDirectorSale82,200$11.14$915.7KForm 4
Nov 24, 2025VARON LESLIE FDirectorBuy9,337$10.71$100.0KForm 4
Mar 3, 2025LUCIER GREGORY TDirectorBuy15,142$16.51$250.0KForm 4
Nov 18, 2024LUCIER GREGORY TDirectorBuy5,000$18.37$91.8KForm 4
Nov 18, 2024LUCIER GREGORY TDirectorBuy5,000$18.37$91.8KForm 4
Nov 15, 2024LUCIER GREGORY TDirectorBuy1,000$18.28$18.3KForm 4
Nov 15, 2024LUCIER GREGORY TDirectorBuy1,000$18.28$18.3KForm 4
Nov 12, 2024Campion Simon DPresident, CEOBuy11,306$17.72$200.3KForm 4
Aug 8, 2024LUCIER GREGORY TDirectorBuy8,212$24.35$200.0KForm 4

All 31 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Simon D. CampionFormer President and Chief Executive Officer$598.2K$10.8M145
2025Daniel T. ScavillaPresident and Chief Executive Officer$431.8K$8.8M145
2025Robert (Tony) A. JohnsonSenior Vice President, Chief Supply Chain Officer$572.4K$5.7M145
2025Richard C. RosenzweigFormer Executive Vice President, Corporate Development, General Counsel and Secretary$452.7K$4.7M145
2025Matthew E. GarthFormer Executive Vice President, Chief Financial Officer$350.7K$3.8M145
2025Andrea L. FrohningSenior Vice President, Chief Human Resources Officer$481.0K$2.4M145
2025Aldo M. DentiExecutive Vice President, Chief Commercial Officer$188.3K$1.5M145
2024Simon D. CampionFormer President and Chief Executive Officer$1.0M$8.7M145
2024Richard C. RosenzweigFormer Executive Vice President, Corporate Development, General Counsel and Secretary$575.4K$2.5M145
2024Robert (Tony) A. JohnsonSenior Vice President, Chief Supply Chain Officer$558.6K$2.2M145
2023Simon D. CampionFormer President and Chief Executive Officer$1.0M$8.5M145
2023Richard C. RosenzweigFormer Executive Vice President, Corporate Development, General Counsel and Secretary$464.1K$4.4M145
2023Robert (Tony) A. JohnsonSenior Vice President, Chief Supply Chain Officer$541.1K$2.9M145

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.26,711,079$283.4M0.0%+7,459,210
Fuller & Thaler Asset Management, Inc.12,697,269$134.7M0.4%−95,249
Vanguard Portfolio Management LLC11,779,851$125.0M0.0%+1,249,105
Aqr Capital Management LLC10,458,771$110.2M0.0%+6,493,548
State Street Corp9,285,298$98.5M0.0%+2,040,461
Vanguard Capital Management LLC9,047,628$96.0M0.0%+48,071
Lazard Asset Management LLC8,269,867$87.7M0.1%+1,554,104
Ariel Investments, LLC8,026,107$85.2M0.8%+1,639,292
Southpoint Capital Advisors LP7,000,000$74.3M1.7%−3,000,000
Cooke & Bieler LP6,927,915$73.5M0.9%−873,272
Geode Capital Management, LLC5,650,605$60.0M0.0%+1,826,968
Invenomic Capital Management LP4,909,808$52.1M3.1%+519,715
Edmond De Rothschild Holding S.a.4,503,300$47.8M0.6%+325,000
Jupiter Asset Management Ltd4,495,136$47.7M0.2%+3,688,171
Allianz Asset Management GmbH3,823,808$40.6M0.0%+877,624
Marshall Wace, Llp3,800,116$40.3M0.0%−708,286
Paradigm Capital Management Inc/ny3,748,800$39.8M1.1%+771,600
Armistice Capital, LLC3,672,000$39.0M1.1%+672,000
Dimensional Fund Advisors LP3,460,636$36.7M0.0%−98,752
D. E. Shaw & Co., Inc.2,987,178$31.7M0.0%+554,459
Neuberger Berman Group LLC2,937,567$31.2M0.0%+1,036,855
Bank Of America Corp /de/2,921,845$31.0M0.0%+489,388
Brickwood Asset Management LLP2,915,389$30.9M22.2%+44,376
Ranmore Fund Management Ltd2,600,000$27.6M3.1%New
Northern Trust Corp2,590,933$27.5M0.0%+836,049

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 8, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseSale$1,001 - $15,000+84.1%Report
Jan 7, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+83.7%Report
Dec 5, 2021Lois FrankelDemocratic, HouseSale$1,001 - $15,000+151.1%Report
Dec 3, 2021Lois FrankelDemocratic, HousePartial sale$1,001 - $15,000+152.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Dentsply Sirona is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDENTSPLY SIRONA Inc.2
  • CIK0000818479
  • Employer ID (EIN)39-143466918
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company18
  • Incorporated inDelaware18
  • Fiscal year endsDecember 312
  • Industry code (SIC)3843 Dental Equipment & Supplies2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address13320 Ballantyne Corporate Place, Charlotte, NC 28277-36072
  • Phone844-546-37222
  • Shares outstanding199,353,876 as of Jul 24, 202616
  • Public float$3.2B as of Jun 30, 202518
  • AuditorDeloitte & Touche LLP, Charlotte, North Carolina PCAOB ID 34; it also attests to the company’s internal control over financial reporting18
  • On EDGAR sinceFeb 13, 19952
  • Filings3,711 in all: 4 (2,819), 8-K (269), 10-Q (95), SC 13G/A (90), 3 (70), 4/A (68), DEF 14A (32), 5 (31)2
    All 41 form types

    10-K (28), SC 13G (25), 11-K (20), DEFA14A (18), UPLOAD (18), 8-K/A (14), SD (13), 425 (12), CORRESP (12), S-8 (8), SCHEDULE 13G (8), SCHEDULE 13G/A (8), 10-Q/A (5), ARS (5), 10-K/A (4), 144 (4), PRE 14A (4), 10-K405 (3), 3/A (3), 424B2 (3), FWP (3), NT 10-Q (3), S-3ASR (3), 424B3 (2), 424B5 (2), NT 10-K (2), DEFR14A (1), EFFECT (1), NO ACT (1), S-3 (1), S-4 (1), S-4/A (1), SC 14D1 (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 23, 2026
    Latest 8-K (8-K) Aug 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $.01 per shareXRAYThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks Dentsply Sirona names in Item 1A of its 10-K filed Feb 26, 2026: 25 risks under these headings, as written.18

  • RISKS RELATED TO OUR BUSINESSES
  • We rely heavily on information technology to operate our businesses and product portfolios, and any cyber incidents could harm our operations and have a material impact on our business and financial results.
  • Evolving governmental oversight of the use of personal information, cross-border data transfer restrictions and the use of emerging technologies, including AI, as well as other technology regulations, may adversely affect our business.
  • Damage to our reputation or brand could negatively impact our business, financial condition or results of operations.
  • We may be unable to execute key strategic initiatives due to competing priorities and strategies of our distribution partners and other factors, which may result in financial losses and operational inefficiencies.
  • Our acquisitions, exiting of businesses, divestitures or strategic investments may result in financial results that are different than expected and create certain risks for our business and operations.
  • We may fail to realize the expected benefits of our strategic initiatives, including executed, announced, or potential future restructuring and other business transformation efforts.
  • We may be unable to develop innovative products and solutions to stimulate customer demand.
  • Our ongoing business operations may be disrupted for a significant period of time, resulting in material operating costs and financial losses.
  • We have recognized substantial goodwill and indefinite-lived intangible asset impairment charges and may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future.
  • Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties.
  • Changes in our credit ratings or macroeconomic impacts on credit markets may increase our cost of capital and limit financing options.
The other 14 risks
  • Our indebtedness could adversely affect our financial condition and prevent us from fulfilling our debt or contractual obligations.
  • Our foreign currency hedging and cash management transactions may be ineffective or only partially mitigate the impact of exchange rate fluctuations, exposing us to unexpected volatility.
  • RISKS RELATED TO OUR GLOBAL OPERATIONS
  • Due to the global nature of our business, including increasing exposure to markets outside of the United States, political or economic changes or other factors could harm our business and financial performance.
  • RISKS RELATED TO OUR REGULATORY ENVIRONMENTS
  • We may be subject to additional litigation and regulatory examinations, investigations, proceedings or court orders relating to the completed 2022 internal investigation regarding certain financial reporting matters. If any of these items are resolved adversely to us, it could harm our business, financial condition and results of operations.
  • We may be unable to obtain necessary product approvals and marketing clearances.
  • Changes in tax rules or interpretations of tax rules, operating structures, transfer pricing regulations, country profitability mix and regulations and tax investigations, audits or other proceedings that we are subject to may harm our business, financial condition and results of operations, including by adversely affecting our effective tax rate.
  • We voluntarily suspended the sale and marketing of our direct-to-consumer Byte aligner systems and impression kits, and subsequently determined to cease offering these aligners to new patients while repurposing Byte technologies and capabilities to support other products within our aligner portfolio. As a result, we have experienced a material impact on our results of operations, and we may be required to take additional significant impairment charges if we are unsuccessful in our efforts to reallocate Byte resources.
  • Inadequate levels of reimbursement from governmental or other third-party payors for procedures using our products may cause our revenue to decline.
  • Challenges may be asserted against our products due to real or perceived quality, health or environmental issues.
  • RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK
  • The market price for our common stock may continue to be volatile as a result of a number of factors, including our quarterly operating results.
  • Certain provisions in our governing documents, and of Delaware law, may make it more difficult for a third party to acquire us.
  • GENERAL RISKS
  • Our business may be adversely affected by changes in global economic conditions, including inflation, rising interest rates, and supply chain shortages.
  • Talent gaps and challenges in managing and retaining top talent may impact our ability to operate effectively, execute strategic initiatives, and deliver for our customers.
  • We face the inherent risk of legal actions, including litigation, product liability claims, and other regulatory or compliance matters.

Legal proceedings

The Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to our business. These legal matters primarily involve stockholder litigation, claims for damages arising out of the use of our products and services, and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury and insurance coverage. We may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations,

warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon our experience, current information and applicable law, we do not believe that these proceedings and claims will have a material adverse effect on our consolidated results of operations, financial position or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. For additional details, see Part II, Item 8, Note 21, Commitments and Contingencies, in the Notes to Consolidated Financial Statements of this Form 10-K, which is incorporated by reference.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceXRAY quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
  118. 118
  119. 119
  120. 120
  121. 121
  122. 122
  123. 123
  124. 124
    SEC EDGAROther events
  125. 125
  126. 126
  127. 127
  128. 128
  129. 129
  130. 130
  131. 131
  132. 132
  133. 133
  134. 134
  135. 135
  136. 136
  137. 137
  138. 138
  139. 139
  140. 140
  141. 141
  142. 142
  143. 143
  144. 144
  145. 145